Treatment of acute cortical infarct with intravenous glycerol : a double-blind, placebo-controlled randomized trial

• Published in: Stroke (1970) 1993-08, Vol.24 (8), p.1119-1124
• Main Authors: YU, Y. L, KUMANA, C. R, LAUDER, I. J, CHEUNG, Y. K, CHAN, F. L, KOU, M, FONG, K. Y, CHEUNG, R. T. F, CHANG, C. M
• Format: Article
• Language: English
• Subjects: Acute Disease; Adult; Aged; Biological and medical sciences; Cerebral Cortex; Cerebral Infarction - blood; Cerebral Infarction - drug therapy; Cerebral Infarction - mortality; Double-Blind Method; Female; Glycerol - adverse effects; Glycerol - therapeutic use; Hemolysis; Humans; Injections, Intravenous; Male; Medical sciences; Middle Aged; Miscellaneous; Neuropharmacology; Pharmacology. Drug treatments; Placebos; Survival Analysis; Treatment Outcome
• ISSN: 0039-2499; 1524-4628
• DOI: 10.1161/01.STR.24.8.1119

This clinical trial investigates the effectiveness of intravenous glycerol therapy in patients with acute cortical infarction in whom intracerebral hemorrhage was rigorously excluded. Within 48 hours of symptoms from their first ischemic stroke, 113 hospital inpatients were randomized into the trial, provided that hemorrhage was excluded by computed tomography and informed consent was obtained. Patients were stratified into alert, semicoma, and coma groups using the Glasgow Coma Scale. Treatment was allocated according to a double-blind, randomized protocol; 56 patients received 500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days, and 57 patients received corresponding placebo treatment with saline. Using a variety of objective scoring systems, patient follow-up was up to 6 months. Corresponding measures of outcome in the glycerol and placebo groups were similar. At 6 months, respective mortality rates were 17 of 56 and 16 of 57, and mean +/- SD improvements in scores were 9.98 +/- 14.40 vs 10.51 +/- 12.68 (long-term), 1.12 +/- 7.20 vs 1.57 +/- 6.30 (prognostic), -1.94 +/- 5.53 vs -2.06 +/- 5.34 (Glasgow Coma Scale), and 21.72 +/- 23.40 vs 11.94 +/- 18.10 (Barthel Index rating in survivors). Hemolysis (generally subclinical) was the only adverse effect. There was no clinically or statistically significant difference in outcome between the groups; a trend toward greater functional recovery among survivors was evident after treatment with glycerol.